
Recent developments regarding multiple myeloma highlight advances in access to medications and funding. [Brazil] Tocantins has incorporated daratumumab into treatment, while [Portugal] the SNS has begun to fund new therapeutic combinations. The approval of medications such as Iberdoma [USA] and the expansion of the Melflufen monograph [USA] are also important milestones.
Made by MielomaAI On November 17, 2026, at 10:32, from recent news. May contain errors. View news →
How much a CAR-T treatment costs and how much the patient pays. Prices negotiated by health services are almost always confidential; here are the public figures.
In euros, per treatment. The USA and Brazil are in the table below, also in euros.
| Country | Public price per treatment | What the patient pays | Source |
|---|---|---|---|
| Portugal | Confidential. Government estimate in 2019: about €350,000. Median total cost at IPO Porto: €355,165. | 0 € in the SNS. Carvykti funded since 26 May 2025. | |
| Spain | €353,000 excluding VAT (deduced from Madrid's public contracts). | €0 in the public system. Carvykti included in the Spanish SNS in April 2025, from the 2nd line. | |
| Germany | A public hospital asked a foreign patient for about €470,000 (2019 report, CAR-T in general). | For residents, paid by health insurance. | Source: Notícias ao Minuto ↗ |
| United Kingdom | No public price for myeloma CAR-T. Carvykti is still being assessed by NICE; Abecma was not assessed because the company did not submit data. | No routine access on the NHS (November 2026). | Source: NICE ↗ |
| USA | 502.452 € (Carvykti, 2025) · 478.024 € (Abecma, 2025) | Depends on insurance; there may be high co-payments. | Source: HMPI 2026 ↗ |
| Brazil | More than 485.846 € (commercial CAR-T). | Outside the SUS; access mainly through the courts and health plans. | Source: Futuro da Saúde ↗ |
Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. List prices do not include confidential discounts.



Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026 / American Society of Hematology (ASH), ASH 2026, cancer care, cancer research

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
All news → · Summaries created by MielomaAI; expand the article to read the original.
